Patents by Inventor Rebecca K. VOTH

Rebecca K. VOTH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS
    Publication number: 20200237794
    Abstract: One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof are provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. For example, the treatment and/or prevention can be for laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.
    Type: Application
    Filed: April 9, 2020
    Publication date: July 30, 2020
    Inventors: Dania Birte REICHE, Nicole MOHREN, Laura JOHNSTON, Bruce SOMERVILLE, Rebecca K. VOTH
  • Treatment of metabolic disorders in equine animals
    Patent number: 10688116
    Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates to one or more SGLT2 inhibitors or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: June 23, 2020
    Inventors: Dania Birte Reiche, Nicole Mohren, Laura Johnston, Bruce Somerville, Rebecca K. Voth
  • TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS
    Publication number: 20150272977
    Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates to one or more SGLT2 inhibitors or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.
    Type: Application
    Filed: March 30, 2015
    Publication date: October 1, 2015
    Inventors: Dania Birte REICHE, Nicole MOHREN, Laura JOHNSTON, Bruce SOMERVILLE, Rebecca K. VOTH